Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation (NASDAQ: DXR) is a medical instrumentation and biotechnology company focused on blood volume measurement, and its news flow centers on developments in this specialized diagnostic area. The company describes itself as the global leader in blood volume measurement technology, with approximately 50 years of experience and a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic platform.
News about Daxor frequently highlights regulatory milestones, such as FDA 510(k) clearance for its next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (Daxor BVA™). Announcements also cover commercial expansion, including adoption of its BVA platform and ezBVA Lab Service by health systems, academic medical centers and cardiology practices, as well as deployments of on-site analyzers for immediate blood volume assessment.
Investors and clinicians following DXR can expect updates on clinical research that evaluates BVA-guided care in conditions like heart failure, LVAD implantation, cardiac amyloidosis, sepsis and COVID-19. Company releases summarize peer-reviewed studies and pilot trials that examine outcomes such as readmissions, survival, kidney injury and hospital length of stay when blood volume analysis is incorporated into care pathways.
Daxor’s news flow also includes participation in medical and investor conferences, where management presents corporate updates and showcases its technology to cardiovascular and critical care audiences, as well as institutional investors. For those tracking DXR, this news page offers a focused view of how the company’s blood volume analysis technology is progressing through regulatory clearance, clinical validation and market adoption over time.
Daxor Corporation (Nasdaq: DXR) announced a study published in the Journal of Cardiac Failure that highlights the effectiveness of its BVA-100 blood test for assessing heart failure. The study demonstrated that traditional surrogate markers fail to measure intravascular volume overload accurately, an essential factor in managing heart failure. The BVA-100 has shown a critical role in reducing hospital readmissions and improving patient outcomes for over 6 million Americans suffering from heart failure. CEO Michael Feldschuh emphasized the test's clinical importance in guiding treatment decisions.
Daxor Corporation (Nasdaq: DXR) will attend the American Heart Association Scientific Sessions from November 5-7, 2022, in Chicago, IL. This event gathers over 15,000 experts in cardiovascular research. The company emphasizes the effectiveness of its BVA guided treatment in heart failure, which can significantly lower 30-day readmissions by 56%, mortality by 82%, and hospital stays by 55%. Daxor's BVA-100® is the first FDA-cleared diagnostic blood test for quantifying blood volume, with over 60,000 tests conducted in leading U.S. hospitals.
Daxor Corporation (Nasdaq: DXR) announced a scientific debate titled "Debating Volume-based versus Pressure-based Methods and Devices to Measure Congestion in Heart Failure" at the Heart Failure Society of America Annual Scientific Meeting on October 3, 2022. Experts agreed that Daxor's BVA-100 blood test, the only FDA-cleared diagnostic for quantifying blood volume, is crucial for managing heart failure. The test has been conducted over 60,000 times in U.S. hospitals, demonstrating its clinical value in improving patient outcomes, including reduced mortality and readmissions.
Daxor Corporation (Nasdaq: DXR) will exhibit at the MedAxiom CV Transforum Fall’22 Conference in Austin, TX, from October 6-8, 2022. This conference gathers cardiovascular leaders to enhance patient care. Daxor's blood volume analysis (BVA) technology shows significant improvements in patient outcomes, including an 82% reduction in 30-day mortality. Daxor recently partnered with MedAxiom to promote BVA adoption among its clinical members. The company's innovations aim to optimize fluid management, enhancing healthcare delivery.
Daxor Corporation (Nasdaq: DXR) announced new findings from the Mayo Clinic at the Heart Failure Society of America meeting, revealing that over 50% of heart failure patients discharged from hospitals had suboptimal treatment based on BVA-100 blood tests. The study measured blood volume among 139 patients, showing persistent intravascular volume expansion post-discharge despite diuretic therapy. CEO Michael Feldschuh emphasized the urgency of blood volume analysis for improved patient outcomes, which could help reduce readmission rates penalized by the Centers for Medicare and Medicaid Services.
Daxor Corporation has announced new findings regarding its BVA-100 diagnostic blood test, which significantly reduces hospital stays for heart failure patients. Presenting at the HFSA Annual Scientific Meeting, the data show that patients receiving BVA-guided care had an average length of stay of 2.04 days, compared to 4.56 days for controls, leading to considerable cost savings. With heart failure treatment costs projected to rise dramatically by 2030, BVA's effectiveness could mitigate financial burdens on hospitals and improve patient outcomes.
Daxor Corporation (NYSE: DXR) presented new research at the HFSA Annual Scientific Meeting highlighting the efficacy of its BVA-100 blood test for heart failure patients. The study demonstrated a 81% reduction in 30-day mortality and an impressive 85% reduction in one-year mortality rates, decreasing from 36.8% to 5.6%. Additionally, there was a 56% lower rate of rehospitalization within 30 days, indicating significant economic advantages. This data underscores the importance of BVA-guided care in improving outcomes for Medicare patients.
Daxor Corporation (NYSE: DXR) recently presented findings from studies at the Heart Failure Society of America Annual Scientific Meeting, confirming the effectiveness of its BVA-100 blood test in managing heart failure. Research from Duke Heart demonstrated that traditional pressure metrics do not correlate with blood volume in heart failure patients. The BVA-100 offers 98% accuracy in blood volume measurement, providing crucial data for therapy optimization. This innovation is vital for enhancing patient outcomes and reducing healthcare costs, reassuring investors of Daxor's commitment to advancing heart failure management.
Daxor Corporation (Nasdaq: DXR) will present new patient outcome data at the Annual Scientific Meeting of the Heart Failure Society of America from September 30 to October 3, 2022, in Washington, DC. Key findings include significant reductions in heart failure readmissions (56%), 30-day mortality (82%), and 1-year mortality (86%) associated with blood volume analysis (BVA). This event will gather leading experts to discuss advancements in heart failure management. Daxor aims to improve healthcare through BVA technology, which has been validated by over 60,000 tests nationwide.
Daxor Corporation (Nasdaq: DXR) announces CEO Michael Feldschuh's participation at the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, in New York. Attendees can request one-on-one meetings with him through the provided registration link. Daxor is renowned for its blood volume measurement technology, particularly the BVA-100®, enabling accurate quantification of blood volume, significantly improving patient outcomes. The company is involved in ongoing trials supported by the NIH, focusing on COVID-19 and heart failure treatment.